What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.

Reza-Thierry Elaidi; Benoit Beuselinck; Agnes Maj-HES; Delphine Carmier; Aristotelis Bamias; Philip R. Debruyne; Camillo Porta; Sophie Roca; Stephane Oudard

doi:10.1200/jco.2012.30.5_suppl.375

What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.

Reza-Thierry Elaidi
, Benoit Beuselinck
, Agnes Maj-HES
, Delphine Carmier
, Aristotelis Bamias
, Philip R. Debruyne
, Camillo Porta
, Sophie Roca
, Stephane Oudard

Medical Oncology Department, Georges Pompidou European Hospital, Paris, France; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Hopital Europeen Georges Pompidou, Paris, France; CHU de Tours, Tours, France; Alexandra Peripheral General Hospital, Athens, Greece; AZ Groeninge Hospital, Kortrijk, Belgium; IRCCS Policlinico San Matteo, Medicina Interna ed Oncologia Medica, Pavia, Italy; CHU de Bordeaux, Bordeaux, France; Georges Pompidou European Hospital, Paris, France

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	375-375
Journal	Journal of Clinical Oncology
Volume	30
Issue number	5_suppl
DOIs	https://doi.org/10.1200/jco.2012.30.5_suppl.375
Publication status	Published - 10 Feb 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2012.30.5_suppl.375

https://ascopubs.org/doi/10.1200/jco.2012.30.5_suppl.375

Cite this

Elaidi, R.-T., Beuselinck, B., Maj-HES, A., Carmier, D., Bamias, A., Debruyne, P. R., Porta, C., Roca, S., & Oudard, S. (2012). What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. Journal of Clinical Oncology, 30(5_suppl), 375-375. https://doi.org/10.1200/jco.2012.30.5_suppl.375

@article{f0f96234e7a14086a7abf49759725186,

title = "What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.",

author = "Reza-Thierry Elaidi and Benoit Beuselinck and Agnes Maj-HES and Delphine Carmier and Aristotelis Bamias and Debruyne, \{Philip R.\} and Camillo Porta and Sophie Roca and Stephane Oudard",

year = "2012",

month = feb,

day = "10",

doi = "10.1200/jco.2012.30.5\_suppl.375",

language = "English",

volume = "30",

pages = "375--375",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "5\_suppl",

}

Elaidi, R-T, Beuselinck, B, Maj-HES, A, Carmier, D, Bamias, A, Debruyne, PR, Porta, C, Roca, S & Oudard, S 2012, 'What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.', Journal of Clinical Oncology, vol. 30, no. 5_suppl, pp. 375-375. https://doi.org/10.1200/jco.2012.30.5_suppl.375

What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. / Elaidi, Reza-Thierry; Beuselinck, Benoit; Maj-HES, Agnes et al.
In: Journal of Clinical Oncology, Vol. 30, No. 5_suppl, 10.02.2012, p. 375-375.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.

AU - Elaidi, Reza-Thierry

AU - Beuselinck, Benoit

AU - Maj-HES, Agnes

AU - Carmier, Delphine

AU - Bamias, Aristotelis

AU - Debruyne, Philip R.

AU - Porta, Camillo

AU - Roca, Sophie

AU - Oudard, Stephane

PY - 2012/2/10

Y1 - 2012/2/10

U2 - 10.1200/jco.2012.30.5_suppl.375

DO - 10.1200/jco.2012.30.5_suppl.375

M3 - Article

SN - 0732-183X

VL - 30

SP - 375

EP - 375

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5_suppl

ER -

Elaidi RT, Beuselinck B, Maj-HES A, Carmier D, Bamias A, Debruyne PR et al. What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. Journal of Clinical Oncology. 2012 Feb 10;30(5_suppl):375-375. doi: 10.1200/jco.2012.30.5_suppl.375